Nucleus Radiopharma, Inc. — Form D
Nucleus Radiopharma, Inc. of PALO ALTO, CA, a company, filed a Form D exempt-offering notice with the SEC on 2024-04-11. The offering totals $6.0M, of which $6.0M was reported sold. Industry: Other Health Care.
Offering
- Filed: 2024-04-11
- Form: D
- Accession: 0002004065-24-000001
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $6.0M
- Amount sold: $6.0M
- Investors: 3
- Date of first sale: 2022-10-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-510388
Issuer
- Name: Nucleus Radiopharma, Inc.
- CIK: 0002004065
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2022
- Address: 514 HIGH STREET, PALO ALTO, CA, 94301
- Phone: 9804833788
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Justin Butler | Director | San Francisco, CA |
| Tyrell Rivers | Director | Chicago, IL |
| Chris McDonald | Director | Golden, CO |
| Mary Kate Wold | Director | Palo Alto, CA |
| Michael Rossi | Director | Palo Alto, CA |
| Norman Sharpless | Director | Palo Alto, CA |
| Manu Nair | Director | Palo Alto, CA |
| Charles Conroy | Director | Palo Alto, CA |
| Charles Conroy | Executive Officer | Palo Alto, CA |
Other filings by this issuer (1)
More